Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408091 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
A Phase 1 study, sponsored by Trellis Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05408091 is a Phase 1 study that has completed, run by Trellis Bioscience. The registered enrollment target is 16 participants.
The verdict
NCT05408091, a Phase 1 study, has completed, sponsored by Trellis Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study in healthy volunteers will provide a basis for evaluation of TRL345 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data, and provide serum samples for ex vivo studies of concentration-dependent antiviral activity to support the dose selection for as well as design and conduct of a clinical study in transplant patients.
Interventions
- DRUG TRL345, a human monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05408091
The ClinicalTrials.gov registry entry for NCT05408091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trellis Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRL345, a human monoclonal antibody is the first listed.
NCT05408091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05408091 about?
NCT05408091 is a clinical study titled "Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers". This study in healthy volunteers will provide a basis for evaluation of TRL345 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data, and provide serum samples for ex vivo studies of concentration-dependent antiviral activity to support the dose selection ...
What is the current status of trial NCT05408091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-09-14. Estimated completion is 2024-12-23.
What interventions are being tested in trial NCT05408091?
The interventions under investigation include: TRL345, a human monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT05408091?
This trial is sponsored by Trellis Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.